All Stories

Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company compared to those of its Danish rival.

Apr 17, 2025 - 21:38
 0
Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company compared to those of its Danish rival.
Read More

Tags:

Previous Article

McDonald’s Snack Wraps Are Coming Back Soon — Mark Your Calendars

Next Article

Virgil Abloh Foundation names new chief creative officer

Related Posts

Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country

Novartis debuts €40M viral vector plant in Slovenia, pa...

Feb 10, 2025  0

Merck KGaA’s EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad

Merck KGaA’s EMD Serono taps Selma Blair to join long-r...

Feb 20, 2025  0

Ionis marks 'milestone event' of Tryngolza launch with first campaigns targeting patients, HCPs

Ionis marks 'milestone event' of Tryngolza launch with ...

Feb 19, 2025  0